https://www.selleckchem.com/pr....oducts/prostaglandin
Multiple active vaccination approaches have proven ineffective in reducing the substantial morbidity and mortality caused by respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a substantial and sustainable boost in neutralising activity is required to protect against severe RSV disease. To that end, we evaluated the safety and immunogenicity of DS-Cav1, a prefusion F subunit vaccine. In this randomised, open-label, phase 1 clinical trial, the stabilised prefusion F vacc
Aimer
Commentaire
Partagez
